Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Rockwell Medical Inc (RMTI), Inovio Pharmaceuticals Inc (INO), Astex Pharmaceuticals, Inc. (ASTX): 3 Humongous Health-Care Stocks This Week

If April brings showers and May brings flowers, what does September bring?

Aside from plenty of football, the first week of September brought some big gains for several health-care stocks. Here are three of the most humongous winners.

Sharpened by iron

Rockwell Medical Inc (NASDAQ:RMTI) lands the top spot on our weekly look at big health-care winners. The biopharmaceutical company’s shares surged nearly 50% this week.

Rockwell Medical Inc

Great results from a phase 3 study of soluble ferric pyrophosphate, or SFP, served as the catalyst. Rockwell Medical Inc (NASDAQ:RMTI) announced that the iron replacement therapy for chronic kidney disease patients on dialysis met its primary and secondary endpoints.

With a solid safety profile in addition to solid efficacy results, Rockwell Medical Inc (NASDAQ:RMTI) now plans to submit a New Drug Application, or NDA, for the anemia drug to the U.S. Food and Drug Administration. If approved, analysts project peak annual sales from $150 million to $225 million.

Big-time interest

Clinical-stage vaccine developer Inovio Pharmaceuticals Inc (NYSEMKT:INO) might be small, but it’s definitely attracted interest from some big-time players. From all appearances, some of those interested parties were doing some buying this week. Inovio’s stock surged almost 43%.

The list of institutional investors with positions in Inovio Pharmaceuticals Inc (NYSEMKT:INO) looks like a who’s-who of major firms, with Vanguard standing atop the group with nearly 3.5 million shares as of June 30. It seems quite possible that a few of these big investors could have been scooping up more shares over the last week. The volume of shares traded was exceptionally high, with more than 16 million shares bought and sold on Friday. For comparison, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s average daily volume over the past three months was just over 8 million shares.

The most likely catalyst for all this action appears to be that Inovio Pharmaceuticals Inc (NYSEMKT:INO) is presenting at two upcoming investor conferences. Dr. J. Joseph Kim, Inovio’s CEO, will speak at the Rodman & Renshaw Global Investment Conference on Sept. 10 and at the Stifel Nicolaus Weisel Healthcare Conference on Sept. 12. Perhaps next week will better explain the reason behind the heavy buying activity over the past few days.

Wind at its sale

A buyout offer from Tokyo-based Otsuka Pharmaceuticals sent shares of Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) soaring. The stock jumped 33% for the week.

Otsuka offered $8.50 per share, a 48% premium over Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)’s average trading price over the past month. That valued Astex at $866 million. Otsuka hopes to take advantage of the smaller company’s Pyramid fragment-based drug discovery technology to help in its own development efforts. Picking up myelodysplastic syndromes drug Dacogen, which Astex markets along with Johnson & Johnson (NYSE:JNJ), was another big plus in the deal for Otsuka.

Despite the huge gains this week, some investors and analysts huffed and puffed at what they saw as a low-ball price for Astex Pharmaceuticals, Inc. (NASDAQ:ASTX). Gene Mack with Brean Capital said that the company should have fetched $13 per share — over 50% more than Otsuka’s offer. Stuart Weisbrod with Iguana Healthcare Partners, which owns some of Astex’s stock, said the deal “will go down as the biggest rip-off of investors in biotech history.”

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.